SKI-G-801

DRUG2 trials

Sponsors

Oscotec Inc.

Conditions

Acute Myeloid LeukemiaAdvanced Solid Tumor

Phase 1

Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)

CompletedNCT03564288

Oscotec Inc.Acute Myeloid Leukemia

Start: 2018-02-23End: 2021-09-02Updated: 2024-02-21

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors

Active, not recruitingNCT05971862

Oscotec Inc.Advanced Solid Tumor

Start: 2022-01-25End: 2024-10-04Target: 36Updated: 2024-02-21